Effectiveness of teriparatide in in improving healing rates and bone-turnover markers of osteoporotic hip fracture: a meta-analysis.

What It Covers

Researchers studied Teriparatide in the context of osteoporosis and bone density in this meta-analysis publication.

To evaluate the effect of subcutaneous teriparatide therapy on fracture healing rate and change in bone mass density in osteoporotic hip fractures.

Who the Included Studies Covered

The meta-analysis was done from September to December 2022, and comprised literature search on Wanfang, CNKI, VIP, PubMed, Embase, Cochrane Library, and Web of Science databases from the establishment of the respective database till December 2022.

The relevant journals of the library of Macao University of Science and Technology, China, were manually searched for randomised controlled trials of teriparatide in the treatment of osteoporotic hip fractures.

How the Review Was Done

The shortlisted studies were subjectd to Cochrane Risk of Bias tool and the Jadad Rating Scale.

Meta-analysis was done using the RevMan 5.4 software provided by the Cochrane Collaboration Network.

Fracture healing rate and bone mineral density were the primary outcome measures, while mortality, adverse events, malformations, complications, subsequent fractures, timed-up-and-go test, visual analogue scale score, and procollagen type I N-terminal propeptide were the secondary outcome measures.

What Was Measured

The subject headings attached to it are Teriparatide, Osteoporotic Fractures, Bone Density Conservation Agents, Hip Fractures, Bone Density, Fracture Healing and Bone Remodeling.

The authors tagged it with the keywords Teriparatide, Osteoporosis, Hip fracture, The fracture healing rate, Bone-turnover markers, Bone density, Fracture union.

What This Means in Plain Language

This is a meta-analysis of Teriparatide in people with osteoporosis and bone density.

Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (JPMA. The Journal of the Pakistan Medical Association), a journal based in Pakistan.

More context: the Teriparatide compound page, Osteoporosis and bone density research.